by Maria Zannes | Mar 6, 2025 | Press Releases
Proactive steps reinforce bioAffinity Technologies’ laser focus on accelerating CyPath® Lung sales growth in strategic national markets Decreases labor and overhead costs, including 38% workforce reduction in non-CyPath® Lung personnel at Company’s subsidiary...
by Maria Zannes | Feb 26, 2025 | Press Releases
SAN ANTONIO, Texas (February 26, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to...
by Maria Zannes | Feb 25, 2025 | Press Releases
SAN ANTONIO, Texas (February 25, 2024) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate...
by Maria Zannes | Jan 22, 2025 | Press Releases
SAN ANTONIO, Texas (Jan. 22, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian...
by Maria Zannes | Jan 13, 2025 | Press Releases
SAN ANTONIO, TX (Jan. 13, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath® Lung...
by Maria Zannes | Dec 17, 2024 | Press Releases
SAN ANTONIO, TX (Dec. 17, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET. The...
